-DOCSTART- -X- O
CVT-E002 -X- _ B-Intervention
( -X- _ I-Intervention
a -X- _ I-Intervention
proprietary -X- _ I-Intervention
extract -X- _ I-Intervention
) -X- _ I-Intervention
was -X- _ O
found -X- _ O
to -X- _ O
be -X- _ O
effective -X- _ O
in -X- _ O
the -X- _ O
prevention -X- _ O
of -X- _ O
upper -X- _ O
respiratory -X- _ O
infections -X- _ O
( -X- _ O
URIs -X- _ O
) -X- _ O
in -X- _ O
healthy -X- _ O
adults -X- _ O
, -X- _ O
and -X- _ O
institutionalized -X- _ O
and -X- _ O
community-dwelling -X- _ O
seniors. -X- _ O
A -X- _ O
multicenter -X- _ O
, -X- _ O
randomized -X- _ O
, -X- _ O
double-blind -X- _ O
, -X- _ O
placebo-controlled -X- _ O
trial -X- _ O
was -X- _ O
carried -X- _ O
out -X- _ O
to -X- _ O
determine -X- _ O
effects -X- _ O
of -X- _ O
CVT-E002 -X- _ B-Intervention
in -X- _ O
the -X- _ O
prevention -X- _ B-Outcome
of -X- _ I-Outcome
URIs -X- _ I-Outcome
in -X- _ O
influenza-vaccinated -X- _ B-Patient
community-dwelling -X- _ I-Patient
adults. -X- _ I-Patient
783 -X- _ O
community-dwelling -X- _ O
adults -X- _ O
were -X- _ O
randomized -X- _ O
to -X- _ O
receive -X- _ O
placebo -X- _ B-Comparison
, -X- _ O
400 -X- _ B-Intervention
mg -X- _ I-Intervention
or -X- _ I-Intervention
800 -X- _ I-Intervention
mg -X- _ I-Intervention
treatment -X- _ I-Intervention
/ -X- _ I-Intervention
d -X- _ I-Intervention
( -X- _ I-Intervention
1 -X- _ I-Intervention
: -X- _ I-Intervention
1 -X- _ I-Intervention
: -X- _ I-Intervention
1 -X- _ I-Intervention
) -X- _ I-Intervention
for -X- _ I-Intervention
6 -X- _ I-Intervention
months. -X- _ I-Intervention
Primary -X- _ O
analysis -X- _ O
on -X- _ O
the -X- _ O
incidence -X- _ O
of -X- _ O
laboratory-confirmed- -X- _ O
clinical -X- _ O
URIs -X- _ O
( -X- _ O
LCCUs -X- _ O
) -X- _ O
, -X- _ O
including -X- _ O
influenza -X- _ O
A -X- _ O
and -X- _ O
B -X- _ O
, -X- _ O
was -X- _ O
performed -X- _ O
on -X- _ O
those -X- _ O
receiving -X- _ O
at -X- _ O
least -X- _ O
one -X- _ O
dose. -X- _ O
Secondary -X- _ O
analysis -X- _ O
was -X- _ O
performed -X- _ O
on -X- _ O
study -X- _ O
completers -X- _ O
and -X- _ O
included -X- _ O
incidence -X- _ O
, -X- _ O
severity -X- _ O
, -X- _ O
and -X- _ O
duration -X- _ O
of -X- _ O
URIs -X- _ O
meeting -X- _ O
a -X- _ O
Jackson-based -X- _ O
criteria -X- _ O
and -X- _ O
safety -X- _ O
of -X- _ O
CVT-E002. -X- _ B-Intervention
The -X- _ O
incidence -X- _ B-Outcome
of -X- _ I-Outcome
LCCUs -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
ITT -X- _ I-Outcome
group -X- _ I-Outcome
was -X- _ I-Outcome
5.5 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
5.2 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
4.6 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
placebo -X- _ I-Outcome
, -X- _ I-Outcome
400 -X- _ I-Outcome
mg -X- _ I-Outcome
and -X- _ I-Outcome
800 -X- _ I-Outcome
mg -X- _ I-Outcome
groups -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.89 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Jackson-confirmed -X- _ I-Outcome
URIs -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
treated -X- _ I-Outcome
groups -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.04 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
CVT-E002 -X- _ I-Outcome
supplementation -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
severity -X- _ I-Outcome
and -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
Jackson-confirmed -X- _ I-Outcome
URIs. -X- _ I-Outcome
The -X- _ O
results -X- _ O
indicate -X- _ O
that -X- _ O
CVT-E002 -X- _ B-Outcome
can -X- _ I-Outcome
be -X- _ I-Outcome
safely -X- _ I-Outcome
used -X- _ I-Outcome
by -X- _ I-Outcome
similar -X- _ I-Outcome
groups -X- _ I-Outcome
and -X- _ I-Outcome
may -X- _ I-Outcome
prevent -X- _ I-Outcome
symptoms -X- _ I-Outcome
of -X- _ I-Outcome
URIs -X- _ I-Outcome
; -X- _ O
larger -X- _ O
sample -X- _ O
size -X- _ O
is -X- _ O
warranted -X- _ O
. -X- _ O

